Supplemental Fig 1: Exogenous d_5-DHA is incorporated into MP phospholipids. Human PMN ($25x10^6$) were incubated with d_5-DHA (5µg) for 30min, 37°C and MPs were collected to assess whether exogenous DHA could be detected within MP phospholipids. Tandem mass spectra of biogenic *(A)* hexadecanoyl-docosahexaenoyl phosphatidylcholine and *(B)* hexadecanoyl-hydroxydocosahexaenoyl phosphatidylcholine. Acyl group positions are arbitrarily assigned. Compounds were identified as acetate adducts in negative ionization mode using Qstar-XL.

Supplemental Fig 2: Microparticles enhance efferocytosis. Human monocyte-derived macrophages (7-day differentiated with 10ng/ml GM-CSF) were seeded at $1x10^5$/well, and vehicle or MPs ($8x10^5$) were added 15min prior to addition of PKH26 (Sigma)-labeled human apoptotic PMN ($3x10^5$). After 1h macrophages were washed and efferocytosis was assessed using a PerkerElmer VICTOR^3 plate reader.

Supplemental Fig 3: Nano-pro-resolving medicines reduce peritoneal PMN infiltration. Human NPRMs ($1x10^4$ - $3x10^5$) were given *(A)* i.v. or *(B)* i.p. as indicated prior to zymosan A (0.1mg, i.p) and peritoneal PMN infiltration was assessed at 2h.

Supplemental Table I: Microparticle fatty acid liberation with $sPLA_2$. Microparticles were collected from zymoan peritonitis (1mg, i.p.) exudates at 48h and incubated with or without human recombinant secretory PLA_2 type V (0.7U, Cayman Chemical) for 30min at 37°C, and liberation of fatty acids was assessed using LC-MS/MS.

Figure S1


A
x 20.0
807.6
255
332
CH_3COO^-
C_2D_5
279.3
282.3
255.3
332.3
532.5
288.3
869.7
417.0
455.0
561.0
785.7
578.9
713.7
837.6
6.0e4
5.0e4
4.0e4
3.0e4
2.0e4
1.0e4
0.0
Intesity, cps
100
200
300
400
500
600
700
800
900
1000
m/z, Da


B
x 5.0
811.6
255
348
CH_3COO^-
C_2D_5
OH
642.6
281.3
885.7
348.3
331.4
255.3
356.3
668.6
822.5
853.6
724.5
750.6
366.3
784.6
7500
6000
4500
3000
1500
0
Intensity, cps
100
200
300
400
500
600
700
800
900
1000
m/z, Da

Figure S2


% increase in efferocytosis above vehicle control
225
200
175
150
125
100
75
50
25
0
Vehicle
Microparticles

Figure S3


A
PMN number (x10^6)
3.0
2.5
2.0
1.5
1.0
0.5
0
**
*
**
Vehicle
10
30
100
300
9,12-benzo-epi-LXA4 NPRM (x10^3)
B
PMN number (x10^6)
3.0
2.5
2.0
1.5
1.0
0.5
0
**
*
Vehicle
i.v.
i.p.
9,12-benzo-epi-LXA4
NPRM (1x10^5)

	DHA (pg)	EPA (pg)	AA (pg)	17-HDHA (pg)*	14-HDHA (pg)*	5-HETE (pg)*	12-HETE (pg)*	15-HETE (pg)*
MP	568	205	855	0.56	2.22	1.62	3.58	2.22
MP + sPLA2	5750	1620	10400	5.8	9.55	15.3	34.6	9.18

Supplemental Table I: Microparticle fatty acid liberation with $sPLA_2$.

*Monohydroxy fatty acids were identified by retention time and multiple reaction monitoring. Transition pairs: 17-HDHA 343, 245; 14-HDHA 343, 205; 5-HETE 319, 115; 12-HETE 319,179 and 15-HETE 319, 219.